MedDataX Logo

Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in Multicenters

NCT ID: NCT00615108

Last Updated: 2014-04-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3148 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observational study is to survey the safety and effectiveness of the product under the real condition of usual practice in Taiwanese hypertensive patients. During the 8-week observation, the safety profiles and the clinical evaluation in between doses through blood pressure (BP) measurement for overall effectiveness of telmisartan therapy will be concluded.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Micardis® in Patients With Essential Hypertension

NCT02187705

Hypertension
COMPLETED

Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension

NCT02245464

Hypertension
COMPLETED

A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension

NCT00133185

Hypertension
COMPLETED PHASE3

Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension

NCT00257491

Hypertension
COMPLETED PHASE3

Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

NCT02242383

Hypertension
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Male or female. 2. Aged 20 to 80 years old. 3. Patients meet one of following two criteria:

1. Adult essential hypertensive either newly diagnosed and untreated, or previously treated and uncontrolled patients; sitting blood pressure: systolic blood pressure (BP) \> 140 mmHg but \< 180 mmHg, and/or diastolic BP \> 90 mmHg but \< 110 mmHg).
2. Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication.

Exclusion Criteria

1. Patients with contraindications to telmisartan use (as per the Micardis® Tablets package insert).
2. Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® Tablets.
3. Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigator Site

Changhua, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 1

Chiayi City, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 2

Chiayi City, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site

Keelung, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site

Ksohsiung, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site

Miaoli, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 1

Taichung, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 2

Taichung, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 1

Tainan City, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 2

Tainan City, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 1

Taipei, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 2

Taipei, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 3

Taipei, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 4

Taipei, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 5

Taipei, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 6

Taipei, , Taiwan

Site Status

Boehringer Ingelheim Investigator Site 7

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.519

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
NCT00946829 COMPLETED
Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension
NCT00659607 COMPLETED
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
NCT02242838 COMPLETED
An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension
NCT00904215 COMPLETED
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
NCT00904371 COMPLETED
Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension
NCT02242370 COMPLETED PHASE4
Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension
NCT02269176 COMPLETED PHASE3
Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
NCT02177422 COMPLETED PHASE3
Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives
NCT00539487 COMPLETED
A Bioequivalence Study Between Telmione 80 mg and Micardis 80 mg in Healthy Adult Volunteers
NCT05223101 UNKNOWN PHASE1
Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
NCT00879411 COMPLETED
Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients
NCT01108809 COMPLETED
An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice
NCT00982735 COMPLETED
J-TARGET,Japanese Telmisartan Study for Antihypertensive Good Effect in Long Term Observation
NCT00659581 COMPLETED
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
NCT00274599 COMPLETED PHASE4
Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects
NCT02262572 COMPLETED PHASE1
A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers
NCT05040880 COMPLETED PHASE1
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
NCT00281593 COMPLETED PHASE3
Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension
NCT02177487 COMPLETED PHASE3
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
NCT00326768 COMPLETED PHASE3
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
NCT01316419 COMPLETED
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
NCT02175355 COMPLETED PHASE3
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
NCT00281580 COMPLETED PHASE3
TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older
NCT02242877 COMPLETED
Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients
NCT00863980 TERMINATED NA